Allen Davidoff

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada.